Latest Breaking News On - Cytokinetics company profile - Page 4 : comparemela.com

Cytokinetics (NASDAQ:CYTK – Get Free Report) had its price objective reduced by equities researchers at Needham & Company LLC from $108.00 to $72.00 in a report released on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Needham & Company LLC’s price target would suggest a potential upside of […]

United statesJohnt hendersonFady ibraham malikJump financialNeedham companyCytokinetics company profileCalifornia public employees retirement systemCytokinetics incorporatedVictory capital management incGet free reportDirector johnIbraham malikRetirement systemPublic employees retirement systemCapital managementState retirement system